Market Closed -
Nasdaq
04:30:01 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.67
USD
|
+6.37%
|
|
+16.78%
|
-15.23%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
66.91
|
48.54
|
71.61
|
10.28
|
26.47
|
27.65
|
-
|
-
|
Enterprise Value (EV)
1 |
75.53
|
76.37
|
71.61
|
10.28
|
26.47
|
27.65
|
27.65
|
27.65
|
P/E ratio
|
-0.63
x
|
-0.46
x
|
-0.7
x
|
-0.23
x
|
-0.67
x
|
-0.71
x
|
-1.62
x
|
-2.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1,808
x
|
-
|
-
|
-
|
-
|
-
|
2.28
x
|
1.06
x
|
EV / Revenue
|
1,808
x
|
-
|
-
|
-
|
-
|
-
|
2.28
x
|
1.06
x
|
EV / EBITDA
|
-656,828
x
|
-1,518,572
x
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-0.85
x
|
-
|
-
|
-
|
-
|
-0.56
x
|
-1.52
x
|
-4.09
x
|
FCF Yield
|
-118%
|
-
|
-
|
-
|
-
|
-179%
|
-65.7%
|
-24.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
991
|
3,272
|
12,185
|
12,233
|
13,435
|
16,555
|
-
|
-
|
Reference price
2 |
67.50
|
14.83
|
5.877
|
0.8400
|
1.970
|
1.670
|
1.670
|
1.670
|
Announcement Date
|
3/12/20
|
3/12/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
0.037
|
-
|
-
|
-
|
-
|
-
|
12.13
|
26.16
|
EBITDA
|
-101.9
|
-31.96
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-102
|
-32.13
|
-24.54
|
-30.38
|
-47.47
|
-38.09
|
-19.69
|
-11.19
|
Operating Margin
|
-275,732.43%
|
-
|
-
|
-
|
-
|
-
|
-162.34%
|
-42.78%
|
Earnings before Tax (EBT)
1 |
-102.7
|
-51.26
|
-90.86
|
-44.13
|
-37.76
|
-38.84
|
-19.71
|
-11.14
|
Net income
1 |
-103.1
|
-52.01
|
-91.56
|
-44.43
|
-38.37
|
-38.94
|
-19.71
|
-11.14
|
Net margin
|
-278,729.73%
|
-
|
-
|
-
|
-
|
-
|
-162.48%
|
-42.58%
|
EPS
2 |
-106.5
|
-32.55
|
-8.400
|
-3.630
|
-2.960
|
-2.350
|
-1.030
|
-0.6000
|
Free Cash Flow
1 |
-78.91
|
-
|
-
|
-
|
-
|
-49.39
|
-18.18
|
-6.752
|
FCF margin
|
-213,267.57%
|
-
|
-
|
-
|
-
|
-
|
-149.83%
|
-25.81%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/12/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.874
|
-6.829
|
-7.373
|
-8.05
|
-7.034
|
-7.926
|
-8.53
|
-10.82
|
-16.68
|
-11.43
|
-10.03
|
-9.776
|
-9.27
|
-9.018
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
4.093
|
-4.011
|
-3.073
|
-6.392
|
-29.68
|
-4.989
|
-9.766
|
-12.06
|
-3.716
|
-12.22
|
-10.22
|
-9.964
|
-9.458
|
-9.205
|
Net income
1 |
3.741
|
-4.182
|
-3.5
|
-6.735
|
-29.11
|
-5.09
|
-9.889
|
-12.24
|
-3.877
|
-12.36
|
-10.24
|
-9.989
|
-9.483
|
-9.23
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
0.3000
|
-0.3000
|
-0.3000
|
-0.6000
|
-2.380
|
-0.4100
|
-0.7800
|
-0.9500
|
-0.3000
|
-0.9400
|
-0.7250
|
-0.5800
|
-0.5450
|
-0.5250
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/12/21
|
3/28/22
|
5/13/22
|
8/12/22
|
11/10/22
|
3/16/23
|
5/12/23
|
8/11/23
|
11/14/23
|
3/28/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
8.62
|
27.8
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-0.0847
x
|
-0.8707
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-78.9
|
-
|
-
|
-
|
-
|
-49.4
|
-18.2
|
-6.75
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.02
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
64.86%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/12/20
|
3/12/21
|
3/28/22
|
3/16/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
1.67
USD Average target price
6.5
USD Spread / Average Target +289.22% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.23% | 27.65M | | +1.51% | 42.75B | | +49.22% | 41.61B | | +8.57% | 41.34B | | -12.36% | 26.59B | | +8.92% | 25.49B | | -25.13% | 18.12B | | +29.17% | 12.24B | | -3.12% | 11.76B | | +6.35% | 11B |
Other Biotechnology & Medical Research
|